EcoDrugPlus

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSDNOG00000046526
Gene Symbol: SIGMAR1
4 Cross references
206 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSDNOG00000007191
Gene Symbol: SIRT1
2 Cross references
159 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSDNOG00000030731
Gene Symbol: SMO
4 Cross references
203 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Alpha

Ensembl ID : ENSDNOG00000036126
Gene Symbol: SCNN1A
4 Cross references
153 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Beta

Ensembl ID : ENSDNOG00000042796
Gene Symbol: SCNN1B
2 Cross references
151 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSDNOG00000035014
Gene Symbol: SCNN1G
2 Cross references
155 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 1

Ensembl ID : ENSDNOG00000005394
Gene Symbol: SCN1A
2 Cross references
140 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSDNOG00000002299
Gene Symbol: SCN10A
2 Cross references
302 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSDNOG00000013849
Gene Symbol: SCN11A
2 Cross references
96 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSDNOG00000011717
Gene Symbol: SCN2A
4 Cross references
130 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSDNOG00000014558
Gene Symbol: SCN3A
2 Cross references
133 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSDNOG00000045978
Gene Symbol: SCN4A
2 Cross references
192 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).